Nationwide Recall: Metallic Particles Found in Retail Business Services, LLC.'s Calcium Carbonate Antacids
Retail Business Services, LLC. faces a nationwide Class II recall for its Calcium Carbonate 1000 mg chewable antacids, initiated by Guardian Drug Co. Inc., due to metallic particle contamination. This event, impacting lot 1716259, underscores critical quality control vulnerabilities. Procurement and regulatory teams must scrutinize supplier quality systems and diversify sourcing to mitigate supply chain risks.
The Recall Event: Metallic Contamination in Calcium Carbonate Antacids
On May 28, 2026, Guardian Drug Co. Inc. initiated a voluntary Class II recall, D-0566-2026, for CAREone, ULTRA STRENGTH CALCIUM ANTACID, Calcium Carbonate 1000 mg chewable tablets. The recall was prompted by the discovery of small metallic particles within the tablets, indicating a critical foreign substance contamination. This specific product, identified by NDC 72476-178-23 and UPC 0341520003516, from lot number 1716259 with an expiration date of March 31, 2029, was manufactured by Retail Business Services, LLC. and distributed by FOODHOLD U.S.A, LLC. The presence of metallic particles in an orally administered human OTC drug poses a potential risk of injury or adverse health consequences, necessitating immediate action. For procurement directors, this event highlights the imperative for stringent quality assurance protocols at every stage of the manufacturing process, particularly for high-volume consumer health products. Supply chain VPs must ensure that their inbound material inspection and finished product release criteria are robust enough to detect such contaminants, preventing widespread distribution of non-compliant goods and safeguarding consumer trust.
Manufacturing & Distribution Chain: Roles of Retail Business Services, LLC. and Guardian Drug Co. Inc.
The recalled Calcium Carbonate 1000 mg product was manufactured by Retail Business Services, LLC., located in Dayton, NJ, United States. This entity is responsible for the primary production of the ULTRA STRENGTH ANTACID ASSORTED BERRIES under the CAREone brand. The distribution network involved FOODHOLD U.S.A, LLC, based in Landover, MD 20785, which handled the broader market reach. Ultimately, Guardian Drug Co. Inc., situated at 2 Charles Ct, Dayton, NJ 08810-1508, was the firm initiating this nationwide recall. This multi-layered supply chain underscores the complexities in tracing accountability and ensuring consistent quality. For business development executives, understanding these intertwined roles is crucial when evaluating potential partnerships or acquisitions within the OTC drug sector. The involvement of multiple parties, from manufacturer to distributor to recalling firm, means that a single quality lapse at any point can trigger a significant market disruption, impacting brand reputation and financial performance across several entities. Regulatory affairs heads must ensure that all partners in their supply chain maintain current Good Manufacturing Practices (cGMP) and have clear recall procedures in place.
Market Exposure: Nationwide Distribution and Brand Impact
The affected CAREone, ULTRA STRENGTH CALCIUM ANTACID, Calcium Carbonate 1000 mg chewable tablets were distributed U.S.A. Nationwide. This broad distribution pattern means that the potential exposure to metallic particles is widespread, affecting numerous retail outlets and consumers across the country. The Class II classification by the FDA indicates that the use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, the commercial implications for the CAREone brand and its associated distributors, including FOODHOLD U.S.A, LLC and Guardian Drug Co. Inc., are substantial. Procurement directors must assess the immediate impact on their inventory of similar antacid products and prepare for potential supply disruptions or increased scrutiny from regulatory bodies. For supply chain VPs, this event necessitates a thorough review of their distribution agreements and product traceability systems to ensure rapid identification and isolation of affected lots in future incidents, minimizing both financial losses and reputational damage.
Sourcing Resilience: Strategies for Calcium Carbonate Supply
The recall of Calcium Carbonate 1000 mg chewable tablets due to metallic contamination highlights the critical need for robust sourcing strategies for active pharmaceutical ingredients (APIs) and finished drug products. While specific alternative suppliers for Calcium Carbonate are not detailed in the available intelligence, procurement directors should proactively identify and qualify multiple manufacturers to mitigate single-point-of-failure risks. This involves a comprehensive due diligence process, including on-site audits, review of quality management systems, and assessment of their regulatory compliance history. Geographic diversity in sourcing is also paramount, reducing exposure to regional disruptions or specific facility-related issues. Qualification timelines for new suppliers can be extensive, often ranging from 6 to 18 months, depending on the complexity of the molecule and regulatory requirements. Therefore, initiating this diversification well in advance of any supply chain event is a strategic imperative to ensure uninterrupted supply of critical OTC medications like Calcium Carbonate antacids.
Guardian Drug Co. Inc.'s Compliance Record: A Pattern of Recalls
This recall of Calcium Carbonate 1000 mg antacids by Guardian Drug Co. Inc. is not an isolated incident. ChemLifeIntel's intelligence reveals a concerning pattern of similar compliance issues for the firm. On the same report date of June 10, 2026, Guardian Drug Co. Inc. was linked to two other Class II nationwide recalls for metallic contamination in calcium carbonate antacids. These include a recall for 'Guardian Drug Co. Inc. Faces Nationwide Recall for Metallic Contamination in Calcium Carbonate Antacids' and another for 'Guardian Drug Co. Inc. Faces Nationwide Class II Recall for HyVee Antacid Due to Metallic Contamination.' This consistent recurrence of metallic particle contamination across multiple calcium carbonate antacid products distributed by Guardian Drug Co. Inc. indicates a systemic issue within their quality control or their manufacturing partners' processes. For regulatory affairs heads, this pattern suggests a heightened risk profile when dealing with Guardian Drug Co. Inc. and necessitates deeper scrutiny of their corrective and preventive actions (CAPAs). Business development executives must factor this history into any potential commercial agreements, recognizing the increased regulatory and reputational risks associated with a firm demonstrating repeated quality failures in a core product category.
Remedial Actions and Future Supply Chain Vigilance
As this recall (D-0566-2026) remains ongoing, Guardian Drug Co. Inc. is expected to implement comprehensive remedial actions to address the root cause of the metallic particle contamination. This typically involves a thorough investigation into manufacturing processes at Retail Business Services, LLC., equipment maintenance, and quality control checkpoints. The firm-initiated nature of the recall indicates a degree of proactivity, yet the recurrence of similar issues across multiple products underscores the need for more effective systemic changes. Regulatory affairs teams should prepare for potential FDA follow-up inspections and requests for detailed CAPA plans. For supply chain VPs, this event serves as a critical reminder to implement continuous monitoring of supplier performance, beyond initial qualification. This includes regular audits, review of quality metrics, and clear contractual clauses regarding product quality and recall responsibilities. Proactive engagement with manufacturers like Retail Business Services, LLC. and distributors like FOODHOLD U.S.A, LLC is essential to ensure that robust quality systems are not just in place, but consistently effective in preventing future contamination events and maintaining product integrity for consumers.